uploads/2018/05/ABMD-PE-MC-1.png

Analyzing ABMD, BR, and TFX Stocks

By

Updated

 Growth stock analysis

Article continues below advertisement

Abiomed

Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively. The company’s pre-tax margin grew from 10.7% in 2013 to 20.5% in 2017. ABMD beat the medical device industry and the S&P 500 between 2013 and 2017. The market cap gained 680% between 2013 and 2017.

ABMD has gained 91.1% on a YTD (year-to-date) basis.

 

Broadridge Financial Solutions

Broadridge Financial Solutions’ (BR) net income has grown at a three-year and five-year average of 7.5% and 21.6%, respectively. The company’s pre-tax margin changed from 13.3% in 2013 to 11.8% in 2017. BR beat the business services industry and the S&P 500 between 2013 and 2017. The market cap gained 124% between 2013 and 2017.

BR has gained 25.7% on a YTD basis.

 

Article continues below advertisement

Teleflex

Teleflex’s (TFX) net income has grown at a three-year and four-year average of -6.6% and 0.3%, respectively. The company’s pre-tax margin grew from 10.4% in 2013 to 13.3% in 2017. TFX beat the medical device industry and the S&P 500 between 2013 and 2017. The market cap gained 190% between 2013 and 2017.

TFX has gained 7.3% on a YTD basis.

Growth stock ETFs

The iShares Russell Midcap Growth ETF (IWP) has 29% exposure to technology. It has a PE (price-to-earnings ratio) of 28.6 and a YTD return of 4.3%. The iShares Nasdaq Biotechnology ETF (IBB) has 99% exposure to healthcare. It has a PE of 22x and a YTD return of -2.8%.

Advertisement

More From Market Realist